Treatment
Table 4. Dosing for Commonly Used Antiplatelet
and Anticoagulant Therapy to Support PCI in
UA/NSTEMI
During PCI
Drug
a
Patient Received
Initial Medical
Treatment (With
a P2Y12 Receptor
Inhibitor)
Patient Did Not Receive Initial Medical
Treatment (With a P2Y12 Receptor
Inhibitor)
GP IIb/IIIa receptor antagonists
Abciximab
Of uncertain
benefit
LD of 0.25 mg/kg IV bolus
MD of 0.125 mcg/kg per min
(maximum 10 mcg/min) (I-A)
Eptifibatide
Of uncertain
benefit
LD of 180 mcg/kg IV bolus followed 10 min
later by second IV bolus of 180 mcg/kg
MD of 2.0 mcg/kg per min, started after
first bolus; reduce infusion by 50% in patients
with estimated creatinine clearance
<50 mL/min (I-A)
Tirofiban
Of uncertain
benefit
LD of 25 mcg/kg IV bolus
MD of IV infusion of 0.15 mcg/kg per min;
reduce rate of infusion by 50% in patients
with estimated creatinine clearance
<30 mL/min (I-B)
P2Y12 receptor inhibitors
Clopidogrelc
If 600 mg given
orally, then
no additional
treatment
A second LD of
300 mg may be
given orally to
supplement a prior
LD of 300 mg (I-C)
LD of 300-600 mg orally (I-A)
MD of 75 mg orally per d (I-A)
MD of 150 mg orally per d for initial 6 d may
be considered (IIb-B)
Prasugreld
No data are
available to
guide decision
making
LD of 60 mg orally (I-B)
MD of 10 mg orally per d (I-B)
18
